SCHEMBL3154138

SCHEMBL3154138

N#Cc1ccc(CNC(=O)c2ccc(S(=O)(=O)Nc3nccs3)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.76
PTPN1 P18031 2/20 0.61
PTPN11 Q06124 2/20 0.61
PTPN22 Q9Y2R2 2/20 0.61
DUSP3 P51452 1/20 0.61
NAMPT P43490 1/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
RXFP1 Q9HBX9 1/20 0.51
EPHX2 P34913 1/20 0.50
PPARA Q07869 1/20 0.49
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.49
CA1 P00915 1/20 0.48
LMNA P02545 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP2C9 P11712 1/20 0.48
EDNRA P25101 1/20 0.48
SLC6A4 P31645 1/20 0.48
ADRA1A P35348 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159069 0.88 SCN3A (0.73) SCN3APTPN1PTPN11PTPN22DUSP3
SCHEMBL3173788 0.86 SCN3A (0.80) SCN3APTPN1PTPN11PTPN22DUSP3
SCHEMBL3159033 0.86 SCN3A (0.81) SCN3APTPN1PTPN11PTPN22NAMPT
SCHEMBL3164238 0.86 SCN3A (0.80) SCN3ANAMPTMEN1KMT2ARXFP1
SCHEMBL3246636 0.86 SCN3A (0.74) SCN3APTPN1PTPN11PTPN22DUSP3
SCHEMBL3161304 0.86 SCN3A (1.00) SCN3ANAMPTMEN1KMT2ARXFP1
SCHEMBL3164261 0.85 SCN3A (0.66) SCN3APTPN1PTPN11PTPN22DUSP3
SCHEMBL3173548 0.84 SCN3A (0.81) SCN3APTPN1PTPN11PTPN22NAMPT
SCHEMBL13452602 0.84 SCN3A (1.00) SCN3APTPN1PTPN11PTPN22NAMPT
SCHEMBL3160008 0.84 SCN3A (0.88) SCN3ANAMPTMEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885PTPN1 814/4885PTPN11 1044/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885PTPN1 814/4885PTPN11 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.